|
| Monday, 28 May 2018, 16:06 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, May 28, 2018 - (JCN Newswire) - Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that an oral presentation on PIII clinical study data on "GOOFICE 5mg Tablet" (nonproprietary name: elobixibat hydrate; development code: AJG533, hereinafter "elobixibat"), a bile acid transporter inhibitor launched in Japan on April 19, 2018, will be given at Digestive Disease Week (DDW) 2018, June 2-5 in Washington D.C., USA.
Elobixibat is a once-daily, orally available constipation treatment1) with a novel action mechanism. EA Pharma in-licensed this product from Albireo AB (Sweden). Elobixibat inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon. The dual action of moisture secretion and bowel movement promotion by bile acids can facilitate defecation. Elobixibat is the world's first pharmaceutical product approved for marketing with the above action mechanism. At DDW2018, safety results obtained from a PIII clinical study and a long-term dosing study will be presented.
Elobixibat was jointly developed by EA Pharma and Mochida. EA Pharma and Mochida distribute elobixibat under the same brand name "GOOFICE 5mg Tablet", respectively, in Japan. EA Pharma and Eisai jointly provide proper use information of "GOOFICE 5mg Tablet" under a co-promotion agreement.
EA Pharma, Eisai and Mochida strive to make a further contribution to improve QOL for patients with chronic constipation through maximization of product value of "GOOFICE 5mg Tablet".
About EA Pharma Co., Ltd.
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 years' history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.
For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/en/
About Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. has been committed to research and development of innovative pharmaceutical products since its establishment thereby providing distinctive medicines to the medical field. Currently, the core pharmaceutical business focuses resources on the targeted areas of cardiovascular, obstetrics and gynecology, dermatology, psychiatry and gastroenterology, while also providing medicine for intractable disease as well as generics including biosimilars, to meet medical needs.
For more information on Mochida Pharmaceutical Co., Ltd., please see
http://www.mochida.co.jp/english/
Contact:
EA Pharma Co., Ltd.
Corporate Planning Dept.
+81(0)3-6280-9802
Mochida Pharmaceutical Co., Ltd.
Public Relations
+81(0)3-3358-7211
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| July 14, 2025 09:20 HKT/SGT |
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout |
| July 8, 2025 08:31 HKT/SGT |
|
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment |
| June 2, 2025 16:46 HKT/SGT |
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan |
| May 28, 2025 16:45 HKT/SGT |
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
| May 21, 2025 14:00 HKT/SGT |
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
| May 16, 2025 16:21 HKT/SGT |
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
| Apr 30, 2025 13:17 HKT/SGT |
|
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
| Apr 18, 2025 15:52 HKT/SGT |
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
| Apr 1, 2025 12:15 HKT/SGT |
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
| Mar 25, 2025 16:28 HKT/SGT |
|
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
| More news >> |
 |
|
|
|
